Role of FXR in β-cells of lean and obese mice

Endocrinology (United States)

Volumn 156, Issue 4, 2015, Pages 1263-1271

  Schittenhelm, Björn ^a   Wagner, Rebecca ^a   Kähny, Verena ^a   Peter, Andreas ^a   Krippeit Drews, Peter ^a   Düfer, Martina ^b   Drews, Gisela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; CALCIUM; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR TGR5; GLUCOSE; GLYCOCHENODEOXYCHOLIC ACID; INSULIN; TAUROCHENODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM SIGNALING; CELL SIZE; CELL STIMULATION; CONTROLLED STUDY; DIET RESTRICTION; EXPERIMENTAL OBESITY; FUNCTIONAL GENOMICS; GENE INACTIVATION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOTOXICITY; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INCUBATION TIME; INSULIN RELEASE; LEAN BODY WEIGHT; LIPID DIET; LIPOTOXICITY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN FUNCTION; WEIGHT GAIN; WILD TYPE; AGONISTS; ANIMAL; DRUG EFFECTS; FEMALE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; OBESITY; SECRETION (PROCESS);

ANIMALS; CHENODEOXYCHOLIC ACID; FEMALE; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; ISOXAZOLES; MALE; MICE; MICE, KNOCKOUT; MICE, OBESE; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TAUROCHENODEOXYCHOLIC ACID;

EID: 84926500879     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1751     Document Type: Article

References (37)

1. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17:657-669.
2. Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal. 2008;20:2180-2197.
3. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci. 2009;30:570-580.
4. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89:147-191.
5. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010; 28:220-224.
6. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta. 2010;1802:363-372.
7. Popescu IR, Helleboid-Chapman A, et al. The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity. FEBS Lett. 2010;584:2845-2851.
8. Düfer M, Hörth K, Wagner R, et al. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes. 2012;61:1479-1489.
9. Seyer P, Vallois D, Poitry-Yamate C, et al. Hepatic glucose sensing is required to preserve β cell glucose competence. J Clin Invest. 2013;123:1662-1676.
10. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006-1011.
11. Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039-11049.
12. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102-1109.
13. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771-784.
14. Watanabe M, Horai Y, Houten SM, et al. Lowering bile acid pool size with a synthetic FXR agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem. 2011;268:26913-26920.
15. Prawitt J, Abdelkarim M, Stroeve JH, et al. Farnesoid x receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011;60:1861-1871.
16. Gier B, Krippeit-Drews P, Sheiko T, et al. Suppression of KATP channel activity protects murine pancreatic β cells against oxidative stress. J Clin Invest. 2009;119:3246-3256.
17. Brufau G, Bahr MJ, Staels B, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond). 2010;7:73.
18. Mroz MS, Keating N, Ward JB, et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut. 2014;63:808-817.
19. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun. 2012;427:600-605.
20. Parks DJ, Blanchard SG, BledsoeR K, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365-1368.
21. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362-1365.
22. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8:e005.
23. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167-177.
24. Dopico AM, Walsh JV Jr, Singer JJ. Natural bile acids and synthetic analogues modulate large conductance Ca2+-activatedK+ (BKCa) channel activity in smooth muscle cells. J Gen Physiol. 2002;119:251-273.
25. Düfer M, Neye Y, Hörth K, et al. BK channels affect glucose homeostasis and cell viability of murine pancreatic β cells. Diabetologia. 2011;54:423-432.
26. Rafferty EP, Wylie AR, Hand KH, Elliott CE, Grieve DJ, Green BD. Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice. Biol Chem. 2011;392:539-546.
27. Sachdeva MM, Stoffers DA. Minireview: meeting the demand for insulin: molecular mechanisms of adaptive postnatal β-cell mass expansion. Mol Endocrinol. 2009;23:747-758.
28. Herrema H, Meissner M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-and liver X receptor α-controlled metabolic pathways in mice. Hepatology. 2010;51:806-816.
29. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140.
30. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev Med Chem. 2011;11:753-762.
31. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59:1899-1905.
32. Staels B, Handelsman Y, Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep. 2010;10:70-77.
33. Brinton EA. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation. Diabetes Obes Metab. 2008;10:1004-1011.
34. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010;52:1455-1464.
35. Uchida K, Makino S, Akiyoshi T. Altered bile acid metabolism in nonobese, spontaneously diabetic (NOD) mice. Diabetes. 1985;34:79-83.
36. Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes. 2013;62:4184-4191.
37. Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014; 509:183-188.